VNS Therapy™ treatment in paediatric patients
Long-term treatment option for children with hard-to-treat seizures1
VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures, which are refractory to antiepileptic medications.2

VNS Therapy™ has been shown to be associated with a reduction of hospitalisations and health related events4
Incidence rates 6 months pre and up to 3 years post VNS Therapy in 207 adolescents with DRE
VNS Therapy™ patients have reported improvements in quality of life6
Limitations of the study included its retrospective design, that it was not designed to explicitly include different severities of childhood epilepsies, and that VNS Therapy dosing was not standardised (although it reflected routine clinical practice).
References
1. Morris GL, et al. Neurology. 2013; 81:1453-9. 2. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 3. Orosz I et al. Epilepsia. 2014 Oct. 55(10):1576-1584. 4. Helmers et al Eur J Paediatr Neurol. 2012 Sep; 16(5):449-58
5. Camfield C et al, Epilepsia 2001, 42(1):104–112 6. Orosz I, et al. Epilepsia. 2014;55(10):1576-84, Patient’s Guide for Epilepsy, November 2021, 1 — 26-0009-9700/4 (OUS) 7. Renfroe et al 2002 Neurology 59 Suppl (4) 8. Soleman et al Epilepsy & Behavior 88 (2018) 139–145